BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 21277618)

  • 21. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM; Gandra SR; Fox KM; Wilson KL
    J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.
    Stokes MB; Foster K; Markowitz GS; Ebrahimi F; Hines W; Kaufman D; Moore B; Wolde D; D'Agati VD
    Nephrol Dial Transplant; 2005 Jul; 20(7):1400-6. PubMed ID: 15840673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.
    Hadjinicolaou AV; Nisar MK; Bhagat S; Parfrey H; Chilvers ER; Ostör AJ
    Rheumatology (Oxford); 2011 Dec; 50(12):2297-305. PubMed ID: 22019799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
    Hochberg MC; Lebwohl MG; Plevy SE; Hobbs KF; Yocum DE
    Semin Arthritis Rheum; 2005 Jun; 34(6):819-36. PubMed ID: 15942917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
    Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
    J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-induced lupus due to anti-tumor necrosis factor alpha agents.
    Costa MF; Said NR; Zimmermann B
    Semin Arthritis Rheum; 2008 Jun; 37(6):381-7. PubMed ID: 17977585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
    Molloy ES; Calabrese LH
    Arthritis Rheum; 2012 Sep; 64(9):3043-51. PubMed ID: 22422012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
    Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
    Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
    Salliot C; Gossec L; Ruyssen-Witrand A; Luc M; Duclos M; Guignard S; Dougados M
    Rheumatology (Oxford); 2007 Feb; 46(2):327-34. PubMed ID: 16880188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Problems encountered during anti-tumour necrosis factor therapy.
    Desai SB; Furst DE
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
    Curtis JR; Sarsour K; Napalkov P; Costa LA; Schulman KL
    Arthritis Res Ther; 2015 Nov; 17():319. PubMed ID: 26555431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.
    Akiyama M; Kaneko Y; Yamaoka K; Kondo H; Takeuchi T
    Rheumatol Int; 2016 Jun; 36(6):881-9. PubMed ID: 27072347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
    J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.
    Wendling D; Paccou J; Berthelot JM; Flipo RM; Guillaume-Czitrom S; Prati C; Dernis E; Direz G; Ferrazzi V; Ristori JM;
    Semin Arthritis Rheum; 2011 Dec; 41(3):503-10. PubMed ID: 21862108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.